Anti-Aging Drug Combination Linked to Severe Brain Damage in Mouse Study

Researchers at the University of Connecticut have identified significant neurological risks associated with the popular anti-aging drug combination of dasatinib and quercetin (D+Q). While the cocktail is frequently studied for its potential to eliminate senescent cells—which contribute to inflammation and age-related decline—this new study reveals that it may inadvertently compromise the brain's structural integrity by damaging myelin, the essential protective coating surrounding nerve fibers.

In experiments involving both young and aged mice, the administration of D+Q led to a dramatic reduction in myelin, particularly within the corpus callosum, a critical structure connecting the brain's hemispheres. The researchers noted that the damage mirrored the cognitive and neurological side effects often described as "chemo brain." Surprisingly, the treatment appeared to be more detrimental to younger mice, suggesting that the drug's impact on brain health is not limited to specific age groups.

Further investigation revealed that the drug combination does not kill the brain's myelin-producing cells, known as oligodendrocytes. Instead, it appears to disrupt their metabolic processes, forcing them to revert to an immature, less functional state. This cellular regression prevents the maintenance of healthy myelin, potentially leading to the cognitive and physical impairments associated with demyelinating conditions.

These findings serve as a critical warning for the longevity community, where D+Q is increasingly used off-label despite limited data on its long-term neurological safety. By highlighting the potential for severe side effects, this research underscores the necessity for rigorous clinical oversight before such therapies are adopted for human anti-aging protocols. Interestingly, the specific cellular damage observed in this study provides researchers with a new model to better understand and potentially develop future treatments for multiple sclerosis.